Detalhe da pesquisa
1.
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
N Engl J Med;
388(23): 2145-2158, 2023 06 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36972026
2.
Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016.
Gynecol Oncol;
186: 61-68, 2024 Apr 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38603953
3.
Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer.
Int J Gynecol Cancer;
34(4): 469-477, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38101816
4.
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design.
Int J Gynecol Cancer;
2024 Apr 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38627035
5.
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.
Lancet;
399(10324): 541-553, 2022 02 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35123694
6.
Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial.
Gynecol Oncol;
175: 1-7, 2023 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37262961
7.
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer.
Gynecol Oncol;
168: 76-82, 2023 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36423446
8.
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.
Gynecol Oncol;
170: 300-308, 2023 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36758420
9.
Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032).
Gynecol Oncol;
178: 161-169, 2023 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37890345
10.
Sequential Targeted Therapy for Advanced, Metastatic, and Recurrent Cervical Cancer: A Cost-Effectiveness Analysis of the Patient Journey.
Cancer Control;
30: 10732748231182795, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37646470
11.
ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer.
Future Oncol;
19(23): 1577-1591, 2023 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37334673
12.
Integrating antibody drug conjugates in the management of gynecologic cancers.
Int J Gynecol Cancer;
33(3): 420-429, 2023 03 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36878560
13.
Biomarker-driven therapy in endometrial cancer.
Int J Gynecol Cancer;
33(3): 343-350, 2023 03 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36878569
14.
Transfusion use and effect on progression-free, overall survival, and quality of life in upfront treatment of advanced epithelial ovarian cancer: evaluation of the European Organization for Research and Treatment EORTC-55971 Cohort.
Int J Gynecol Cancer;
33(1): 1-9, 2023 01 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36356982
15.
Evaluating open access publication and research impact in gynecologic oncology.
Int J Gynecol Cancer;
33(7): 1112-1117, 2023 07 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37220951
16.
Systemic therapy de-escalation in advanced ovarian cancer: a new era on the horizon?
Int J Gynecol Cancer;
33(9): 1448-1457, 2023 09 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37597852
17.
Can fluorescence-guided surgery improve optimal surgical treatment for ovarian cancer? A systematic scoping review of clinical studies.
Int J Gynecol Cancer;
33(4): 549-561, 2023 04 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36707085
18.
Exploring international differences in ovarian cancer care: a survey report on global patterns of care, current practices, and barriers.
Int J Gynecol Cancer;
33(10): 1612-1620, 2023 10 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37591611
19.
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.
Int J Gynecol Cancer;
33(4): 562-570, 2023 04 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36564099
20.
Low-grade serous ovarian cancer: expert consensus report on the state of the science.
Int J Gynecol Cancer;
33(9): 1331-1344, 2023 09 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37591609